Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 434

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 434
---
2011, we entered into an exclusive license agreement with JHU for rights to certain biomatrix technology. The JHU License includes royalties upon commercial sales of any products utilizing the licensed technology and also includes minimum annual royalties, development milestone payments and a commercialization milestone payment. We are also obligated to reimburse JHU for patent maintenance costs incurred for the licensed intellectual property.

In December 2022, we entered into an amendment to the license agreement with JHU whereby the terms were modified to cancel the balance due for minimum annual royalties and to defer future minimum annual royalty obligations.

The following tables summarizes our balances with JHU outstanding as of September 30, 2024, December 31, 2023 and 2022:

| Obligation                           |     | 2024 | September 
       30, |     | 2023 | December 
      31, |     | 2022 |        |
|:-------------------------------------|:----|:-----|----------:|:----|:-----|---------:|:----|:-----|-------:|
| Patent                               
 maintenance reimbursement obligation |     | $    |    62,551 |     | $    |   58,038 |     | $    | 43,408 |
| Minimum                              
 annual royalties                     |     |      |         — |     |      |        — |     |      |      — |

Quantitative and Qualitative Disclosures about Market Risks

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of interest rate fluctuations.

| 238 |

<div align='center'>CEREVAST MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div>

In this section, unless the context otherwise requires, references to “Cerevast,” “we,” “us” and “our” are intended to mean the business and operations of Cerevast. Additional terms used by Cerevast are defined in the Glossary and in this Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with the financial statements and related notes of Cerevast included elsewhere in this proxy statement/prospectus. This discussion contains forward- looking statements reflecting Cerevast’s current expectations, estimates and assumptions concerning events

and financial trends that may